Arun

Pencil Sketch's annual mid-year retrospective on Indian corporate office design — 40+ delivered projects, three concurrent Bayer engagements, a Certificate of Appreciation from Bayer HUB, four cities operational. What changed in 2026, what recycled marketing content is still noise, and where the market is going.

A retrospective on rapid scaling, integrated delivery, and what it takes to maintain quality while moving fast in commercial interior design.

What we learned building 60,000+ sq.ft workspaces for fast-growth tech companies. Modular planning, phased delivery, and infrastructure thinking.

The coordination failures plaguing traditional design-bid-build projects, and how integrated delivery fixes them.

Delivering 2,500-4,500 sq.ft workspaces that feel spacious, functional, and professional despite limited area.

How Pencil Sketch maintains design standards across Hyderabad, Bengaluru, Chennai and Coimbatore while adapting to local conditions.

Why Pencil Sketch avoids decorative excess and thematic design in favor of functional materials and architectural clarity.

Searching for the best office interior designers in Hyderabad? Here is what separates competent commercial design firms from the ones that will burn your budget and timeline.

What is genuinely shifting in 2026 Indian corporate workspaces — and what is recycled marketing content. Based on data from 40+ delivered projects.

The open office debate is not binary. Here is how to design the right mix of open, enclosed, and hybrid workspace based on actual work patterns.

Planning an office interior in Bengaluru? Everything you need to know—tech park regulations, pricing, vendor landscape, and what makes the city unique for commercial design.

A 5,000 sq.ft office is not small—it is compact. Here is how to design one that functions like a space twice its size, with real layout strategies and project references.

Pharmaceutical offices are not standard corporate spaces. Here are the design requirements, material specifications, and compliance standards that pharma companies in India must address.